Protagonist Therapeutics Inc
NASDAQ:PTGX
Balance Sheet
Balance Sheet Decomposition
Protagonist Therapeutics Inc
Protagonist Therapeutics Inc
Balance Sheet
Protagonist Therapeutics Inc
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
9
|
4
|
21
|
106
|
82
|
33
|
117
|
124
|
126
|
187
|
97
|
128
|
|
| Cash Equivalents |
9
|
4
|
21
|
106
|
82
|
33
|
117
|
124
|
126
|
187
|
97
|
128
|
|
| Short-Term Investments |
0
|
8
|
57
|
38
|
47
|
100
|
189
|
203
|
112
|
155
|
322
|
439
|
|
| Total Receivables |
1
|
1
|
2
|
3
|
7
|
8
|
4
|
5
|
0
|
10
|
168
|
4
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
4
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
165
|
0
|
|
| Other Current Assets |
0
|
2
|
3
|
4
|
2
|
5
|
6
|
9
|
6
|
4
|
4
|
6
|
|
| Total Current Assets |
10
|
14
|
83
|
151
|
138
|
145
|
316
|
341
|
243
|
356
|
592
|
578
|
|
| PP&E Net |
0
|
1
|
1
|
1
|
1
|
8
|
6
|
7
|
5
|
2
|
13
|
12
|
|
| PP&E Gross |
0
|
1
|
1
|
1
|
1
|
8
|
6
|
7
|
5
|
2
|
13
|
12
|
|
| Accumulated Depreciation |
1
|
1
|
1
|
2
|
2
|
3
|
4
|
4
|
5
|
6
|
7
|
8
|
|
| Long-Term Investments |
0
|
0
|
10
|
12
|
0
|
0
|
2
|
0
|
0
|
0
|
140
|
79
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
1
|
1
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
10
N/A
|
15
+44%
|
94
+535%
|
164
+74%
|
140
-15%
|
155
+11%
|
325
+109%
|
348
+7%
|
248
-29%
|
358
+44%
|
745
+108%
|
668
-10%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
0
|
1
|
1
|
1
|
6
|
3
|
3
|
2
|
4
|
1
|
2
|
5
|
|
| Accrued Liabilities |
1
|
2
|
5
|
9
|
11
|
14
|
20
|
40
|
27
|
20
|
24
|
30
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
32
|
9
|
19
|
17
|
3
|
1
|
0
|
22
|
10
|
|
| Total Current Liabilities |
1
|
3
|
6
|
43
|
26
|
35
|
40
|
44
|
31
|
21
|
47
|
45
|
|
| Long-Term Debt |
1
|
2
|
0
|
0
|
0
|
10
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
1
|
1
|
30
|
5
|
4
|
1
|
0
|
22
|
8
|
|
| Total Liabilities |
2
N/A
|
5
+117%
|
6
+23%
|
43
+573%
|
27
-37%
|
75
+178%
|
45
-40%
|
48
+6%
|
32
-32%
|
21
-34%
|
69
+226%
|
53
-23%
|
|
| Equity | |||||||||||||
| Common Stock |
21
|
37
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
13
|
27
|
65
|
102
|
141
|
218
|
284
|
409
|
537
|
616
|
341
|
471
|
|
| Additional Paid In Capital |
0
|
0
|
152
|
222
|
253
|
298
|
563
|
710
|
753
|
952
|
1 016
|
1 085
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Total Equity |
8
N/A
|
10
+20%
|
88
+813%
|
121
+38%
|
113
-7%
|
80
-29%
|
280
+250%
|
300
+7%
|
216
-28%
|
337
+56%
|
675
+101%
|
615
-9%
|
|
| Total Liabilities & Equity |
10
N/A
|
15
+44%
|
94
+535%
|
164
+74%
|
140
-15%
|
155
+11%
|
325
+109%
|
348
+7%
|
248
-29%
|
358
+44%
|
745
+108%
|
668
-10%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
15
|
15
|
15
|
21
|
23
|
27
|
44
|
48
|
49
|
58
|
61
|
63
|
|